Linked Life Data

14620791

Source:http://linkedlifedata.com/resource/pubmed/id/14620791

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5 Suppl
pubmed:dateCreated
2003-11-17
pubmed:abstractText
VTE is a major but often-overlooked healthcare problem resulting in significant morbidity, mortality, and resource expenditures. The efficacy of anticoagulation therapy has been well documented in patients with The availability of LMWHs has advanced treatment of VTE by allowing for effective anticoagulation without the need for dose adjustments and routine monitoring. In addition, patients with uncomplicated DVT can be safely treated in the outpatient setting, allowing for shorter hospital stays and cost savings. LMWHs have been replacing traditional anticoagulants and are now considered the antithrombotic agents of choice in the initial treatment of VTE. Research on additional novel anticoagulants such as DTIs and factor Xa inhibitors is promising. These agents may offer potential benefits over current therapies, but their exact role in clinical practice remains to be determined pending additional ongoing clinical studies. Benefit-to-risk analyses will be necessary for determining how effective novel therapies will compare with established regimens.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
H
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1088-0224
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S103-14; quiz S115-20
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Antithrombotic therapy for the treatment of venous thromboembolism.
pubmed:affiliation
Department of Pharmacy Practice, The University of Illinois at Chicago, College of Pharmacy, USA.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't